Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study

by Cimbora, D., Cree, B.A.C, Drappa, J., Flanagan, E.P, Katz, E., Levy, M., Mealy, M.A, She, D.
Published 2022

Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders

by Abboud, H., Alroughani, R., Altintas, A., Apiwattanakul, M., Asgari, N., Basuroski, I.D, Bennett, J., Bichuetti, D.B, Blaschke, T.F, Boyko, A., Broadley, S., Carnero Contentti, E., Cohen, J.A, de Castillo, I.S, Delgado-Garcia, G., Flores-Rivera, J., Fujihara, K., George, N., Goodman, A., Havla, J., Hellwig, K., Hor, J.Y, Huda, S., Iorio, R., Jarius, S., Kimbrough, D., Kissani, N., Kister, I., Kleiter, I., Lana-Peixoto, M., Leite, M.I, Levy, M., Maiga, Y., Mao-Draayer, Y., Mariotto, S., Matiello, M., Mealy, M.A, Melamed, E., Neubrand, V.E, On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium, Oreja-Guevara, C., Palace, J., Paolilo, R.B, Planchon, S.M, Pröbstel, A.-K, Qian, P., Quan, C., Riley, C., Ringelstein, M., Sa, M.J, Salazar-Camelo, A., Siritho, S., Smith, T.J, Tenembaum, S., Villoslada, P., Wingerchuk, D., Wuerfel, J., Yamout, B., Yeaman, M.
Published 2022